The expression and significance of insulin-like growth factor-1 receptor and its pathway on breast cancer stem/progenitors
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Introduction: Dysregulation of the insulin-like growth factor-1 receptor (IGF-1R)/phosphatidylinositol-3-kinase (PI3K)/Akt pathway was shown to correlate with breast cancer disease progression. Cancer stem cells are a subpopulation within cancer cells that participate in tumor initiation, radio/chemoresistance and metastasis. In breast cancer, breast cancer stem cells (BCSCs) were identified as CD24-CD44+ cells or cells with high intracellular aldehyde dehydrogenase activity (ALDH+). Elucidation of the role of IGF-1R in BCSCs is crucial to the design of breast cancer therapies targeting BCSCs. Methods: IGF-1R expression in BCSCs and noncancer stem cells sorted from xenografts of human primary breast cancers was examined by fluorescence-activated cell sorting (FACS), western blot analysis and immunoprecipitation. The role of IGF-1R in BCSCs was assessed by IGF-1R blockade with chemical inhibitor and gene silencing. Involvement of PI3K/Akt/mammalian target of rapamycin (mTOR) as the downstream pathway was studied by their phosphorylation status upon IGF-1R inhibition and the effects of chemical inhibitors of these signaling molecules on BCSCs. We also studied 16 clinical specimens of breast cancer for the expression of phosphor-Akt in the BCSCs by FACS. Results: Expression of phosphorylated IGF-1R was greater in BCSCs than in non-BCSCs from xenografts of human breast cancer, which were supported by western blot and immunoprecipitation experiments. The sorted IGF-1R-expressing cells displayed features of cancer stem/progenitors such as mammosphere formation in vitro and tumorigenicity in vivo, both of which were suppressed by knockdown of IGF-1R. A specific inhibitor of the IGF-1R, picropodophyllin suppressed phospho-Akt Ser473 and preferentially decreased ALDH+ BCSC populations of human breast cancer cells. Furthermore, picropodophyllin inhibited the capacity of CD24-CD44+ BCSCs to undergo the epithelial-mesenchymal transition process with downregulation of mesenchymal markers. Inhibitors of signal molecules downstream of IGF-1R including PI3K/Akt/mTOR also reduced the ALDH+ population of breast cancer cells. Furthermore, the mTOR inhibitor, rapamycin, suppressed BCSCs in vitro and in vivo. Conclusion: Our data support the notion that IGF-1R is a marker of stemness, and IGF-1R and its downstream PI3K/Akt/mTOR pathway are attractive targets for therapy directed against breast cancer stem/progenitors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nowell, P. C. (1976) · Science · doi:10.1126/science.959840 · Cited by 6,471
A cell initiating human acute myeloid leukaemia after transplantation into SCID mice
Lapidot, T., Sirard, C., Vormoor, J., Murdoch, B., Hoang, T., Caceres-Cortes, J., Minden, M., Paterson, B., Caligiuri, M. A., & Dick, J. E. (1994) · Nature · doi:10.1038/367645a0 · Cited by 4,783 · cited 1×
“The existence of cancer stem cells (CSCs) has been reported in a variety of malignancies, including leukemia [3], and solid tumors such as brain cancer [4], breast cancer [5], and colon cancer [6].”
Blume-Jensen, P., & Hunter, T. (2001) · Nature · doi:10.1038/35077225 · Cited by 3,738
Insulin and insulin-like growth factor signalling in neoplasia
Pollak, M. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2536 · Cited by 2,059 · cited 1×
“One of the growth receptors associated with activation of Akt is insulin-like growth factor-1 receptor (IGF-1R), which can turn on the signaling cascade of the PI3K/Akt/ mammalian target of rapamycin (mTOR) pathway upon stimulation with insulin-like growth factor-1 (IGF-1) [16].”
Regulation of mammary stem/progenitor cells by PTEN/Akt/β-catenin signaling
Korkaya, H., Paulson, A., Charafe-Jauffret, E., Ginestier, C., Brown, M., Dutcher, J., Clouthier, S. G., & Wicha, M. S. (2009) · PLoS Biology · doi:10.1371/journal.pbio.1000121 · Cited by 523 · cited 3×
“Korkaya and colleagues demonstrated that phosphatase and tensin homolog knockdown increased phosphorylation of Akt, leading to enriched normal and malignant mammary stem/progenitor cells, and that this Akt-driven process was mediated by the Wnt/b-catenin pathway [46].”
Shan, J., Shen, J., Liu, L., Xia, F., Xu, C., Duan, G., Xu, Y., Ma, Q., Yang, Z., Zhang, Q., et al. (2012) · Hepatology · doi:10.1002/hep.25745 · Cited by 296 · cited 1×
“In hepatocellular carcinoma, the IGF-2/IGF-1R signal was shown to be involved in Nanog-mediated self-renewal of hepatic CSCs [39].”
Naing, A., LoRusso, P., Fu, S., Hong, D. S., Anderson, P., Benjamin, R. S., Ludwig, J., Chen, H. X., Doyle, L. A., & Kurzrock, R. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0061 · Cited by 205 · cited 1×
“Also, combination of IGF-1R and mTOR inhibition showed clinical benefits in Ewing’s sarcoma [52].”
Zhang, H., Pelzer, A. M., Kiang, D. T., & Yee, D. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-1712 · Cited by 162
Cited by
Panwar, V., Singh, A., Bhatt, M., Tonk, R. K., Azizov, S., Raza, A. S., Sengupta, S., Kumar, D., & Garg, M. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01608-z · Cited by 967
“138 Hoshii et al. have generated conditional knockouts of Raptor , a component of mTORC1.”
BackgroundThe role of the insulin-like growth factor-1 system in breast cancer
Christopoulos, P. F., Msaouel, P., & Koutsilieris, M. (2015) · Molecular Cancer · doi:10.1186/s12943-015-0291-7 · Cited by 376
Targeting EMT in cancer: opportunities for pharmacological intervention
Davis, F. M., Stewart, T. A., Thompson, E. W., & Monteith, G. R. (2014) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2014.06.006 · Cited by 361
Hua, H., Kong, Q., Yin, J., Zhang, J., & Jiang, Y. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00904-3 · Cited by 273
Lee, K.-L., Kuo, Y.-C., Ho, Y.-S., & Huang, Y.-H. (2019) · Cancers · doi:10.3390/cancers11091334 · Cited by 260
Kaipio, K., Chen, P., Roering, P., Huhtinen, K., Mikkonen, P., Östling, P., Lehtinen, L., Mansuri, N., Korpela, T., Potdar, S., et al. (2020) · The Journal of Pathology · doi:10.1002/path.5356 · Cited by 54
“Interestingly, IGF-1R, a transmembrane tyrosine kinase receptor that transmits signals via the AKT-PI3K or MAPK–ERK pathways, has been associated with CSC functionality in ovarian cancer, as well as tumorigenicity and maintenance of a CSC phenotype in breast cancer [41,42].”
BackgroundHe, L., Zhang, S., Zhang, X., Liu, R., Guan, H., & Zhang, H. (2017) · OncoTargets and Therapy · doi:10.2147/ott.s150701 · Cited by 40
Metadata
- Authors
- Chang, W.-W., Lin, R.-J., Yu, J., Chang, W.-Y., Fu, C.-H., Lai, A. C.-Y., Yu, J.-C., & Yu, A. L.
- Venue
- Breast Cancer Research
- Published
- 2013-05-12
- Volume
- 15
- Issue
- 3
- Pages
- R39-R39
- ISSN
- 1465-5411 (ISSN-L)
- 1465-542X
- OpenAlex
- W2132063594
- Cited by
- 108
- References
- 8
- FWCI
- 5.22
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.